

(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended		Year to Date		Quarter Ended		Year to Date	
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
PART I								
1. Income from Operations								
a. Net Sales/Income from Operations (Net of excise duty)	18,651.48	15,472.80	15,105.13	78,011.30	13,739.44	13,075.43	13,753.56	70,222.16
b. Other Operating Income	542.59	319.28	553.05	1,963.93	576.02	338.08	553.05	2,006.25
Total Income from operations (net)	19,194.07	15,792.08	15,658.18	79,975.23	14,315.46	13,413.51	14,306.61	72,228.41
2. Expenses								
a. Cost of materials consumed	3,706.22	2,399.68	2,293.57	11,873.05	-	-	2,293.57	7,616.28
b. Purchase of stock-in- trade	4,345.81	4,844.13	4,531.61	26,274.43	12,891.55	12,259.03	4,112.95	37,267.94
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(350.23)	(610.33)	360.59	(2,691.47)	-	-	377.42	(427.69)
d. Employee benefits expense	1,840.84	2,942.30	2,131.95	9,257.02	527.75	1,664.02	1,952.61	6,661.50
e. Depreciation and amortisation expense	1,037.29	891.75	1,031.64	4,904.83	174.97	86.42	843.41	2,957.56
f. Other expenses	4,741.23	3,861.80	3,502.01	19,714.87	890.86	896.09	3,250.63	12,475.07
Total Expenses	15,321.16	14,329.33	13,851.37	69,332.73	14,485.13	14,905.56	12,830.59	66,550.66
3. Profit / (Loss) from Operations before Other Income, finance costs and exceptional Items (1-2)	3,872.91	1,462.75	1,806.81	10,642.50	(169.67)	(1,492.05)	1,476.02	5,677.75
4. Other Income	858.36	1,378.38	1,305.14	8,630.35	1,045.36	1,973.61	1,379.69	7,625.52
5. Profit / (Loss) from ordinary activities before finance costs and exceptional Items (3+4)	4,731.27	2,841.13	3,111.95	19,272.85	875.69	481.56	2,855.71	13,303.27
6. Finance Costs	1,022.72	1,045.89	909.18	4,826.04	42.88	58.49	904.86	3,104.40
7. Profit / (Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	3,708.55	1,795.24	2,202.77	14,446.81	832.81	423.07	1,950.85	10,198.87
8. Exceptional Items [Income / (Expense)]	-	-	-	-	-	-	-	523.03
9. Profit / (Loss) from Ordinary Activities before tax (7+8)	3,708.55	1,795.24	2,202.77	14,446.81	832.81	423.07	1,950.85	10,721.90
10. Tax Expense	1,475.88	545.09	596.08	(1,220.36)	191.03	38.65	590.80	(3,147.06)
11. Net Profit / (Loss) from Ordinary Activities after tax (9-10)	2,232.67	1,250.15	1,606.69	15,667.17	641.78	384.42	1,360.05	13,868.96
12. Extraordinary Item	-	-	-	-	-	-	-	-
13. Net Profit / (Loss) for the period (11-12)	2,232.67	1,250.15	1,606.69	15,667.17	641.78	384.42	1,360.05	13,868.96
14. Share in Profit/(Loss) from Associate	(204.03)	(206.02)	(58.90)	(719.18)	-	-	-	-
15. Minority interest	-	-	-	-	-	-	-	-
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	2,028.64	1,044.13	1,547.79	14,947.99	641.78	384.42	1,360.05	13,868.96
17. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78	5,456.78
18. Reserve excluding Revaluation Reserves (As per Balance Sheet of previous accounting year)	-	-	-	126,214.11	-	-	-	80,300.36
19. Basic and Diluted Earnings Per Share (EPS) (before & after extraordinary items) (of Rs. 10/- each) (Not Annualised)	3.72	1.91	2.53	25.89	1.18	0.70	2.22	24.02
See accompanying note to the financial results								



(Rs.in Lacs except EPS and Shares)

Particulars	Consolidated				Standalone			
	Quarter Ended		Year to Date		Quarter Ended		Year to Date	
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
PART II								
A PARTICULARS OF SHAREHOLDING								
1. Public Shareholding								
- Number of shares	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801	21,285,801
- Percentage of shareholding	39.01	39.01	39.01	39.01	39.01	39.01	39.01	39.01
2. Promoters and Promoter group shareholding								
a) Pledged/Encumbered								
- Number of shares	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384	5,928,384
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.81	17.81	17.81	17.81	17.81	17.81	17.81	17.81
- Percentage of shares (as a % of the total share capital of the Company)	10.86	10.86	10.86	10.86	10.86	10.86	10.86	10.86
b) Non-encumbered								
- Number of Shares	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580	27,353,580
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	82.19	82.19	82.19	82.19	82.19	82.19	82.19	82.19
- Percentage of shares (as a % of the total share capital of the Company)	50.13	50.13	50.13	50.13	50.13	50.13	50.13	50.13
B INVESTOR COMPLAINTS								
Pending at the beginning of the quarter					NIL			
Received during the quarter					NIL			
Disposed of during the quarter					NIL			
Remaining unresolved at the end of the quarter					NIL			



Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13th August, 2015
- 2 Consequent to the applicability of Companies Act, 2013 (The Act) to accounting periods commencing from 1st April 2015 to the Company, the Company has charged depreciation on various fixed assets as per the useful lives specified in part C of Schedule II of the Companies Act 2013. The carrying value, net-off residual value of the fixed assets whose useful lives are already exhausted on 31st March 2015 have been adjusted to retained earnings. Had there not been any change in useful lives of the fixed assets as compared to previous quarter, depreciation for the current quarter would have been lower by Rs. 85.84 lacs.
- 3 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 4 During the financial period of fifteen months ended on 31st March, 2015, on receipt of necessary approvals from Board of Directors and Shareholders of the Company at their meetings held on 4th July, 2014 and 3rd September, 2014 respectively in respect of transfer of its Injectables Business on Slump Sale basis, the Company has transferred its Injectables Business to its wholly owned subsidiary namely Claris Injectables Limited (formerly known as Claris Lifesciences International Limited) on 31st October, 2014. The business transfer involved transfer of relevant assets and liabilities as stated in the Business Transfer Agreement of Injectables Business on a "slump sale basis" for an agreed cash consideration of Rs. 55,400 lacs. The Company has registered a profit of Rs 523.03 lacs on account of slump sale of Injectables Business.

The key financial number pertaining to the discontinued business :

(Rs in Lacs)

Particulars	Consolidated				Standalone			
	Quarter Ended		Period ended		Quarter Ended		*Period ended	
	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015	30th June 2015	31st Mar 2015	30th June 2014	31st Mar 2015
	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
				15 months				15 months
Revenue	-	-	-	-	-	-	12,220.88	35,254.24
Expenditure	-	-	-	-	-	-	10,668.76	29,591.40
PBT	-	-	-	-	-	-	1,552.12	5,662.84
PAT	-	-	-	-	-	-	1,105.30	4,010.53
Particulars	Consolidated period ended				Standalone period ended			
	31st Oct 2014				31st Oct 2014			
	Unaudited				Unaudited			
Total Assets				-				102,163.15
Total Liabilities				-				47,286.18

* The Company Operates in single segment and in the view of the common expenditure - employee, marketing expenses, logistic & distribution arrangements and general corporate overheads are not separately identifiable for the identified products. However, the figures of Profit Before Tax and Profit After Tax for the period 1st January, 2014 to 31st March, 2015 have been apportioned and calculated on best estimated basis. Since the Business has been transferred to wholly owned subsidiary, there is no impact on consolidated financial results of the Company due to transfer of Injectable Business (i.e. Discontinued Operation).

- 5 In the standalone financial result for the fifteen months period ended on 31st March, 2015 (audited), the exceptional item stated therein of Rs. 523.03 lacs pertains to profit on transfer of Injectables Business to Claris Injectables Limited, the wholly owned subsidiary of the Company, on a slump sale basis as stated in note 4 above.
- 6 The figures for the previous quarter and year have been regrouped / rearranged, wherever necessary.



Place: Ahmedabad
Date: 13th August, 2015



For Claris Lifesciences Limited

Chandrasingh S Purohit
Chandrasingh S Purohit
Whole-time Director & CFO

LIMITED REVIEW REPORT

To

**THE BOARD OF DIRECTORS OF
CLARIS LIFESCIENCES LIMITED**

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **CLARIS LIFESCIENCES LIMITED** ('the Company') and also the Statement of Consolidated Unaudited Financial Results of the Company and its subsidiaries (the Company and its subsidiaries constitute "the Group") and the company's share of the profit / (loss) of its associate for the 1st Quarter ended on 30th June, 2015 (the "Statement"), being submitted by the Company pursuant to Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures in Part II - Select Information referred to in paragraph 6 below. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a review report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. The Group includes the results of the following entities:

(i) PT. Claris Lifesciences Indonesia, (ii) Claris Lifesciences Colombia Ltda., (iii) Catalys Venture Cap Limited, (iv) Claris Lifesciences Venezuela C. A. (v) Claris Lifesciences Inc. (vi) Claris Lifesciences (UK) Limited (vii) Claris Lifesciences & CIA Chile Limitada, (viii) Claris Lifesciences (Aust) Pty Limited (ix) Claris



Lifesciences de Mexico S.A. de C.V. (x) Claris Produtos Farmaceuticos do Brasil Ltda.(xi) Claris Lifesciences Philippines, Inc. (xii) Claris Infrastructure Limited, (xiii) Claris SteriOne, (xiv) Claris Pharmaservices, (xv) iCubix Infotech Limited, (xvi) Claris Injectables Limited, (xvii) Ogen Nutrition Limited, (xviii) Claris Middle East FZ-LLC, Dubai, (xix) Elda International DMCC, (xx) Claris Capital Limited

4. We did not review the quarterly/Interim financial statements of sixteen subsidiaries included in the consolidated financial results, whose interim financial statements reflect, total revenues of Rs.8861.77 Lacs for the Quarter ended 30th June, 2015 and total profit / (loss) after tax of (Rs.5014.32 Lacs) for the Quarter ended 30th June, 2015 as considered in the consolidated financial results. These quarterly /Interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors.
5. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred in paragraph 4 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the Accounting Standards notified under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. Further, we also report that we have traced the number of shares as well as the percentage of shareholdings in respect of the aggregate amount of public shareholdings and the number of share as well as the percentage of shares pledged/encumbered and non-encumbered in respect of the aggregate amount of promoters and promoter group shareholding in terms of Clause 35 of the Listing Agreements and the particulars relating to investor complaints disclosed in Part II - Select information for the Quarter Ended 30th June, 2015 of the Statement, from the details furnished by the Registrar and are, therefore, not expressing a review opinion thereon.



SHAH & SHAH ASSOCIATES
CHARTERED ACCOUNTANTS

702, ANIKET,
Nr. MUNICIPAL MARKET,
C.G. ROAD, NAVRANGPURA,
AHMEDABAD - 380 009.
PHONE: 26465433
FAX : 079 - 26406983
Email: ca@shahandshah.co.in

7. Without qualifying our report, we draw attention to note no: 4 of the notes to the above referred statement regarding disclosure of certain information required under Accounting Standard-24 "Discontinuing Operations", for the reasons mentioned in the said note.

For **SHAH & SHAH ASSOCIATES**
Chartered Accountants
F.R.N. No. 113742W



Place : Ahmedabad
Date : 13th August, 2015


PARTNER
SUNIL K. DAVE
Membership Number: 047236

CLARIS LIFESCIENCES LIMITED UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2015

Ahmedabad, India, 13th August 2015: Claris Lifesciences Ltd. (CLL) today announced its Un-Audited Financial Results for the quarter ended 30th June 2015 at its board meeting held at its registered office in Ahmedabad.

Management Representation of the Financial of the Speciality Injectable Business:

(Values in Rupees Mn)

Particulars	Q1FY16 (Apr to Jun 2015)	Previous Quarter (Jan to Mar 2015)	Growth
Net Sales	1,459	1,117	31%
EBITDA	520	404	29%
EBITDA Margin (%age)	36%	36%	
PAT	208	182	14%
PAT Margin (%age)	14%	16%	

Key financial highlights of the Specialty Injectable Business:

- Net Sales for Q1FY15 stood at Rs. 1,459 mn, which has grown by around 31% as compared to the previous quarter.
- EBITDA has grown by 29%; to Rs. 520 mn; over the previous quarter.
- EBITDA margins for the quarter stood at 36%, in line with the margins for the previous quarter.
- Net Profit for the quarter stood at Rs. 208 mn the Profit during the previous quarter stood at Rs. 182 mn, showing a growth of 14% quarter on quarter.
- Assuming this quarter will account for around 25% of the full year sales, the speciality injectables business can be expected to achieve around Rs. 5,800 mn of sales for FY2016.


Region wise Net Sales

(Values in Rupees Mn)

Region	Q1FY16 (Apr to Jun 2015)	Previous Quarter (Jan to Mar 2015)	Growth
USA	534	503	6%
Other Regulated (Ex US) - ORM	347	248	40%
Emerging Markets- EM	578	366	58%
TOTAL	1,459	1,117	31%



- USA sales were in line the previous quarter, showed a modest growth of 6% quarter on quarter and accounted for 36% of the overall sales for the quarter.
- The US sales have largely remained flat due to supplies issues from some of its raw material suppliers, these issues have now been resolved with alternate vendors being identified and added to the ANDAs.
- This quarter saw growth from the Emerging Markets and Other Regulated Markets (ex USA)
- Other Regulated Markets grew at 40% quarter on quarter and accounted for 24% of the overall sales for the quarter.
- Emerging Markets also saw good traction of products during the quarter, with sales increasing to Rs. 578 mn over Rs. 366 mn in the previous quarter, showing a growth of 58% quarter on quarter. Emerging Markets accounted for 40% of the sales during the quarter.



Key financial highlights of the consolidated financials of Claris Lifesciences Ltd.:

(Values in Rupees Mn)

Particulars	Q1FY16 (Apr to Jun 2015)	Q1FY15 (Apr to Jun 2014)	Growth
Net Income	1,919.41	1,563.50	23%
EBITDA	576.86	414.36	39%
EBITDA%	30%	27%	
PAT	202.86	154.78	31%
PAT%	11%	10%	

REVENUE

- The Net Revenue for the quarter stood at Rs. 1,919 mn and it grew by 23% over the same quarter last year.
- During the quarter, pass thought sales of COL accounted for Rs. 419 mn this stood at 24% of the overall net income for the quarter.



EBITDA

- The EBITDA for the quarter grew to Rs. 577 mn and by 39% over the same quarter last year.
- The EBITDA margin for the quarter stood at 30% as compared to the 27% in the same quarter last year, the increased margin is due to increase in own product sales vs the pass through sales of COL.
- As the pass through sales of COL reduces the revenue may reduce, but this would positively affect the margins of the business going forward.

PAT

- The PAT for the quarter grew by 31%; to Rs. 203 mn; over the same quarter last year.
- The PAT margins for the quarter stood at 11% as compared to 10% in the same quarter last year.

###

Disclaimer

This press release may include "forward-looking statements" which involve a number of risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future. Claris Lifesciences Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Market information mentioned in the press release is based on IMS Data and/or internal estimates of the company. The press release also contains the carved out financials of the business transferred to Claris Injectables Limited (CIL), these carved out business are management representations and are not audited numbers.

About Claris Lifesciences Limited (CLL)

Claris Lifesciences Limited (BSE Code: 533288) the Company with three segmental revenues, (i) the Speciality Injectables Business which is housed in a wholly owned subsidiary; Claris Injectables Limited, (ii) 20% stake in the Joint Venture with Otsuka and Mitsui for the Infusion Business in India and Emerging Markets, and (iii) the Treasury and Cash management for the funds in the Holding Company.

For more information about the company, log on to: www.clarislifesciences.com

About Claris Injectables Limited (CIL)

Claris Injectables Limited is one of the largest sterile injectables pharmaceutical companies in India. The company manufactures and/or markets products across various therapeutic segments including Anesthesia, Plasma Volume Expanders, Blood Products, Parenteral, Infusion therapy, Anti-infective and Renal Care. A significant majority of these products are generic drugs that are capable of being directly injected into the human body and are predominantly used in the treatment of critical illnesses.


The company has 3 manufacturing plants; at its campus on the outskirts of Ahmedabad. With emphasis on Quality, Technology & Innovation, Claris offers a range of niche technology-driven injectable products across delivery systems such as glass bottles, glass vials & ampoules, and non-PVC/PVC bags. Claris' sterile injectables facilities have been approved by regulatory authorities including USFDA, MHRA (UK), TGA (Australia), and GCC FDCA. The company's manufacturing capabilities have several times received awards from prestigious institutions like Frost & Sullivan and IDMA.

For more information about the company, log on to: www.clarisinj.com

About COL Private Limited (COPL)

COL Private Ltd. (COL) is a Joint Venture between Claris Lifesciences Ltd., India, Otsuka Pharmaceutical Factory, Inc., Japan and Mitsui & Co. Ltd., Japan, for Claris' Infusion Business in India and Emerging Markets. The company primarily manufactures & markets products across multiple markets and therapeutic segments. COL, a leader in intravenous nutrition products, is committed to being the best partner of patients and healthcare professionals in the field of clinical nutrition.

The company has products ranging across various therapeutic segments, including infusion therapy, parenteral nutrition, anti-infectives, and plasma volume expanders. We offer injectables in various delivery systems, such as glass and plastic bottles (EURO Head & Nipple Head), ampoules, and non-PVC/PVC bags.





The company's customer base primarily includes government and private hospitals, aid agencies, and nursing homes.

The company has two state-of-the-art plants at our manufacturing facility located in Ahmedabad, India. One of the facilities has been approved by foreign regulatory authorities including ANVISA (Brasil).

For more information about the company, log on to: www.clarisotsuka.com

